Basic Information
INFANRIX IPV+HIB VACCINE
INJECTION
Regulatory Information
SIN10988P
June 25, 1999
Prescription Only
Therapeutic
INTRAMUSCULAR
August 10, 2023
June 3, 2025
XJ07CA06
Company Information
GLAXOSMITHKLINE PTE LTD
GLAXOSMITHKLINE PTE LTD
Active Ingredients
Strength: min 30IU/0.5ml
Strength: min 40IU/0.5ml
Strength: 25mcg/0.5ml
Strength: 25mcg/0.5ml
Strength: 10 mcg/0.5 ml
Strength: 8DU/0.5ml
Strength: 8mcg/0.5ml
Strength: 32DU/0.5ml
Strength: 40DU/0.5ml
Detailed Information
Contraindications
**Contraindications** _**Infanrix-IPV+Hib**_ should not be administered to subjects with known hypersensitivity to any component of the vaccine, or to subjects having shown signs of hypersensitivity after previous administration of diphtheria, tetanus, pertussis, inactivated polio or Hib vaccines. _**Infanrix-IPV+Hib**_ is contraindicated if the child has experienced an encephalopathy of unknown aetiology, occurring within 7 days following previous vaccination with pertussis-containing vaccine.
Indication Information
**Indications** _**Infanrix-IPV+Hib**_ is indicated for active immunisation in infants from the age of 2 months against diphtheria, tetanus, pertussis, poliomyelitis and _Haemophilus influenzae_ type b. _**Infanrix-IPV+Hib**_ is also indicated as a booster dose for children who have previously been immunised with diphtheria, tetanus, pertussis (DTP), polio and Hib antigens. _**Infanrix-IPV+Hib**_ does not protect against diseases caused by other types of _Haemophilus influenzae_ nor against meningitis caused by other organisms.